与性别肯定激素治疗相关的血栓形成风险
Tanya L Kowalczyk Mullins1, Eric S Mullins2
1Division of Adolescent and Transition Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA; Department of Pediatrics, University of Cincinnati, College of Medicine, Cincinnati, Ohio, USA.
Journal of thrombosis and haemostasis : JTH
|May 25, 2024
概括
使用雌激素或的性别肯定激素治疗 (GAHT) 可以改变血液凝固因素. 使用雌激素的跨性别女性可能面临更高的血栓形成风险,而丸激素则面临更高的血栓形成风险.
科学领域:
- 内分泌学 在内分泌学.
- 血液学 血液学 血液学
- 跨性别者健康 跨性别者健康
背景情况:
- 变性人和性别扩张 (TG) 个体经常经历性别障碍症,影响健康.
- 性别肯定激素治疗 (GAHT) 是管理性别失调症的关键干预措施.
- 雌激素和丸激素是GAHT中用于分别女性化和男性化的主要激素.
研究的目的:
- 审查由于外源性雌激素和的血静参数的变化.
- 总结目前关于与TG群体中GAHT相关的血栓形成风险的知识.
- 为了突出血液学家管理TG患者的知识差距.
主要方法:
- 对外源性雌激素和的血液静止和血栓形成风险研究的文献综述.
- 分析血栓前因子,凝血抑制剂,血红蛋白和血红素的变化.
- 在使用这些激素的 cisgender 和跨性别人群中检查血栓形成风险.
主要成果:
- 在 cisgender 女性中使用雌激素会增加血栓前因子和血栓形成风险.
- 雌激素的跨性别女性似乎有较高的动脉和静脉血栓形成的风险.
- 的使用增加了血红蛋白和血红素,可能会增加血栓形成的风险,尽管研究结果是混合的.
结论:
- 涉及雌激素和的GAHT显著影响静血参数.
- 了解这些激素的影响对于评估和管理TG个体的血栓形成风险至关重要.
- 需要进一步的研究来澄清混合的发现,特别是对于治疗.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
681
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
681
Disorders of Hemostasis
845
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
845
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
521
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
521
Disorders of the Female Reproductive System
354
The female reproductive system can be affected by several disorders, including Premenstrual Syndrome (PMS), Premenstrual Dysphoric Disorder (PMDD), endometriosis, and various forms of cancer. PMS and PMDD are cyclical conditions that cause physical and emotional distress, with symptoms that include edema, mood swings, and food cravings. PMDD is a more severe form of PMS characterized by increased symptom severity that peaks during the luteal phase and tends to improve or resolve shortly after...
354
Hormonal Regulation of the Menstrual Cycle
345
The ovarian cycle regulates endometrial changes throughout a single menstrual cycle via the coordinated action of gonadotrophin-releasing hormone (GnRH) and gonadotrophins.
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH...
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH...
345
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K


